
Micrima
Develops and commercializes microwave radar breast imaging technology.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
£3.8m | Convertible | ||
Total Funding | 000k |
Related Content
Micrima, a company spun out of the University of Bristol, has developed an innovative breast imaging system known as MARIA. This system utilizes microwave radar technology, a non-invasive and non-ionizing method for detecting breast cancer.
The MARIA system offers a significant advancement in breast cancer screening by providing a radiation-free and painless alternative to traditional mammography. This makes the screening process more comfortable and safer for patients, potentially encouraging more frequent and earlier testing.
Micrima's business model is focused on the development and commercialization of this technology, targeting healthcare providers such as hospitals and clinics as its primary clients. The company generates revenue through the sale of its MARIA imaging systems. The market for this technology is the global medical device industry, specifically in the area of breast cancer diagnostics, a sector with a continuous demand for more effective and patient-friendly solutions.
Keywords: breast imaging, microwave radar, medical devices, cancer diagnostics, non-invasive, radiation-free, healthcare technology, oncology, women's health, medical imaging